RudaCure a établi RudaCure U.S.A. Inc. to expand its presence in the États-Unis.
The U.S. subsidiary devrait serve as the headquarters for future U.S. essais cliniques of RCI002, ainsi que to attract U.S. local investissements under the Bio iCORE project, develop U.S. grants, and act as a forward base for open innovation.
The U.S. address is 40W. 37th St. Suite 801, New York, NY 10018.